From a virus's point of view, invading our cells is a matter of survival. The virus makes a living by highjacking cellular processes to produce more of the proteins that make it up. From our point of ...
The FDA granted priority review, with a decision expected by June 19, 2025. LEN represents a novel class of HIV therapies by targeting the viral capsid, a multifunctional protein essential for HIV ...
A novel bioengineering strategy utilizing peptide display technology on the AAV1 capsid has successfully generated ...
Biologists have engineered adeno-associated viruses that are better at capsid filling, potentially resulting in higher productivity.
The efficacy of adeno-associated virus (AAV)-mediated gene therapy for the inner ear is fundamentally constrained by the natural tropism of viral ...
A reduction of the retrotransposon at the Drosophila NMJ leads to a drastic increase in synaptogenesis and plasticity (-copia). The structure of Copia (center), shows a large retroviral like structure ...
Viral vectors and vaccines navigate public distrust while advancing through AI design, COVID response lessons, and promising ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir (LEN), a groundbreaking twice-yearly injectable HIV-1 capsid inhibitor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results